戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 astectomy should not be regarded as equal to breast conservation.
2 forming patients with BRCA variants choosing breast conservation.
3  with early-stage breast cancer treated with breast conservation.
4  underutilized in eligible patients desiring breast conservation.
5 er (BC) can downstage disease and facilitate breast conservation.
6 f tumor size to breast size may still permit breast conservation.
7 reast event even among patients eligible for breast conservation.
8 n is indicated for all patients treated with breast conservation.
9 evidence suggesting no survival benefit over breast conservation.
10 kelihood of adjuvant radiation therapy after breast conservation.
11       All women were clinically eligible for breast conservation.
12 nts with breast cancer have some options for breast conservation.
13 2.12 (P = 0.008)]; re-excision after initial breast conservation 10.9% versus 18.0% [OR, 0.56 (P = 0.
14 3.06 (P < 0.001)]; re-excision after initial breast conservation 11.6% versus 11.4% [OR, 1.02 (P = 0.
15 (41%, P =.004), and fewer patients underwent breast conservation (36%, P =.036).
16 more frequently treated with mastectomy than breast conservation (771 [76.5%] vs 297 [29.5%]; P < .00
17                                         This breast-conservation accelerated hyperfractionation radia
18                               The success of breast conservation after preoperative chemotherapy depe
19 mary chemotherapy offers a greater chance of breast conservation (although no survival advantage), an
20 C, with 28% of patients being candidates for breast conservation and a 5-year overall survival rate o
21 en difficult as there are trade-offs between breast conservation and adverse effects, and women with
22 rted cosmetic satisfaction was similar after breast conservation and after mastectomy with reconstruc
23                              Patients having breast conservation and mastectomies had adjusted median
24 cinoma in situ and in invasive cancers after breast conservation and mastectomy.
25 uctal carcinoma in situ to considerations in breast conservation and prevention is highlighted.
26                                            A breast conservation and radiation regimen has significan
27 cremental cost-effectiveness ratio comparing breast conservation and radiation to mastectomy was $219
28 ents who develop breast recurrence following breast conservation and SLN biopsy.
29 atients with early breast cancer planned for breast conservation and SLND.
30 ed SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLN
31 eoperative MRI, and unsuccessful attempts at breast conservation, are associated with increased rates
32 hould be taken into account when considering breast conservation as a treatment option.
33                          Women who preferred breast conservation but received mastectomy had the poor
34                                      Whether breast-conservation can be safely offered to BRCA1/2 mut
35 mammoplasty technique is a viable option for breast conservation even for larger tumors, combining a
36 st benefit from the addition of radiation in breast conservation for ductal carcinoma in situ (DCIS)
37  in the risk of recurrence has been shown in breast conservation for ductal carcinoma in situ and in
38 t-sided irradiation in patients treated with breast conservation for early-stage breast cancer who su
39                       Patients operated with breast conservation for relatively low-risk breast cance
40 de biopsy increased more than twofold in the breast conservation group (an average of 23% in 1998 ver
41                           Women who received breast conservation had better body image 2 years after
42 e favorable tumors, were more likely to have breast conservation, had a lower median predicted risk o
43                                           As breast conservation has increasingly substituted mastect
44  with left-sided radiation as a component of breast conservation have an increased risk of late, radi
45 urgery, can greatly increase the options for breast conservation in complex cancer cases.
46 r, a higher percentage of patients underwent breast conservation in the breast surgeon period than in
47 pared with no surgery in patients undergoing breast conservation in women with predominantly small, e
48 tients with breast cancer, particularly when breast conservation is contemplated.
49 erapy in the population of patients choosing breast conservation is important.
50                                     Although breast conservation is therapeutically equivalent to mas
51                          Efforts to optimize breast conservation, minimize unnecessary tests, and imp
52 ugh the definitive procedure, whether it was breast conservation or mastectomy.
53             Compared with patients who chose breast conservation or unilateral mastectomy, those who
54 s paclitaxel (15.7%; P = .02), with improved breast conservation rates (P = .05).
55 ble breast cancer allows a small increase in breast conservation rates and has significant potential
56 able breast cancer has been shown to improve breast conservation rates as a result of tumor response
57 vasive breast cancer and potential impact on breast conservation rates.
58 ystemic therapy is effective and can improve breast conservation rates.
59                 Opportunities for increasing breast-conservation rates through improved XRT access ex
60                                              Breast-conservation rates were 30% in the node-negative
61 ropriate imaging guidelines for recommending breast conservation surgery (BCS) after the NAC.
62 y (NET) on the response rate and the rate of breast conservation surgery (BCS) for ER+ breast cancer.
63  of this study was to determine the trend of breast conservation surgery (BCS) in North Carolina over
64 United States are measured on performance of breast conservation surgery (BCS) in the majority of wom
65               For early-stage breast cancer, breast conservation surgery (BCS) is a conservative opti
66 ved unilateral mastectomy and 22.8% received breast conservation surgery (BCS).
67 ted in three patients, two of whom underwent breast conservation surgery (group III).
68 ncreased incidence of local recurrence after breast conservation surgery and radiation therapy.
69 or women with early breast cancer undergoing breast conservation surgery and radiotherapy, there are
70              Local cancer relapse risk after breast conservation surgery followed by radiotherapy has
71 e-fourth of all patients who undergo initial breast conservation surgery for breast cancer will have
72 they were aged 50 years or older and had had breast conservation surgery for unifocal invasive ductal
73 e effect of adjuvant radiotherapy (RT) after breast conservation surgery in different breast cancer s
74 of providing a choice between mastectomy and breast conservation surgery is economically attractive w
75 inoma of the breast (pT1-3, pN0-1, M0) after breast conservation surgery or mastectomy were eligible.
76 breast cancer must choose between undergoing breast conservation surgery or mastectomy.
77 rmore, patients in the NLBx group undergoing breast conservation surgery required re-excision more fr
78  0 to II breast cancer who underwent initial breast conservation surgery were studied.
79  is similar in BRCA1/2 carriers treated with breast conservation surgery who undergo oophorectomy ver
80  Radiotherapy trial between 1991 and 1997 to breast conservation surgery with or without RT.
81 t of CPM (vs either unilateral mastectomy or breast conservation surgery) was significantly associate
82 re is currently no standard margin width for breast conservation surgery.
83 ategorized as CPM, unilateral mastectomy, or breast conservation surgery.
84 ratified by centre, type of primary surgery (breast-conservation surgery or mastectomy), and tumour b
85        Two hundred patients, 112 of whom had breast-conservation surgery with axillary dissection and
86 uction have improved cosmetic outcomes after breast-conservation surgery.
87 ve neoadjuvant induction chemotherapy before breast-conservation surgery.
88 r some women to be successfully treated with breast conservation therapy (BCT ) who were initially co
89 We investigated rates of radiation use after breast conservation therapy (BCT) for patients treated f
90 s done to determine the long-term outcome of breast conservation therapy (BCT) for patients with earl
91 studies that directly compare survival after breast conservation therapy (BCT) vs mastectomy.
92                                              Breast conservation therapy after neoadjuvant chemothera
93 n, data from a previously published study of breast conservation therapy among women of Ashkenazi des
94 s were selected, including 8108 who received breast conservation therapy and 13,488 who received mast
95 sfaction was similar between those receiving breast conservation therapy and those receiving mastecto
96           TNBC is not a contraindication for breast conservation therapy because data suggest increas
97                  Review of special issues in breast conservation therapy demonstrates no benefit to e
98                    The long-term efficacy of breast conservation therapy for early breast cancer cont
99 d be obtained in patients who have undergone breast conservation therapy only when considered necessa
100 ce risks (relative to luminal subtypes) with breast conservation therapy or mastectomy.
101                                              Breast conservation therapy was performed in 310 cases i
102                                              Breast conservation therapy was used to treat 70% of pat
103                                              Breast conservation therapy, mastectomy alone, or mastec
104 al surgical resection has been supplanted by breast conservation therapy.
105 7 patients with biopsy-proven ILC undergoing breast-conservation therapy (BCT) at the University of V
106         Whole-breast irradiation, as part of breast-conservation therapy (BCT), has well-established
107                    In local recurrence after breast-conservation therapy for DCIS, histopathologic fi
108 al of 447 (7.9%) of 5660 patients undergoing breast-conservation therapy from 1970 to 2005 experience
109 om re-excision to mastectomy (n = 3) or from breast-conservation therapy to mastectomy (n = 1).
110  26 patients with 27 local recurrences after breast-conservation therapy were identified.
111 ts, 11 underwent mastectomy, seven underwent breast-conservation therapy, and one did not undergo a s
112                                        After breast-conservation therapy, IBTR may be classified into
113 mph node-negative breast cancer treated with breast-conservation therapy.
114                        Patients treated with breast conservation, those with 10 or more positive node
115 ith stage I or II breast cancer treated with breast conservation treatment were reviewed.
116  who underwent breast MRI during work-up for breast conservation treatment.
117 ss than 10%) absolute increase in the use of breast-conservation treatment (BCT) with similar rates o
118 umpectomy and whole-breast radiotherapy (ie, breast-conservation treatment) are accepted as viable al
119  We present a 30-year update of the Scottish Breast Conservation Trial.
120 ty-five patients (94.9%) achieved successful breast conservation, whereas 4 patients (5.1%) went on t
121 sitivity analysis was based on women who had breast conservation with radiotherapy.

 
Page Top